Differential expression of interleukin-4 (IL-4) and IL-4δ2 mRNA, but not transforming growth factor beta (TGF-β), TGF-βRII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment

Clinical and Vaccine Immunology

Volumn 15, Issue 8, 2008, Pages 1165-1170

  Siawaya, Joel Fleury Djoba ^a   Bapela, Nchinya Bennedict ^a   Ronacher, Katharina ^a   Beyers, Nulda ^a   Van Helden, Paul ^a   Walzl, Gerhard ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 4; ISONIAZID; MESSENGER RNA; PYRAZINAMIDE; RIFAMPICIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HUMAN; INTERFERON PRODUCTION; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SPUTUM CULTURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SPUTUM; T-BOX DOMAIN PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 49149109715     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00084-08     Document Type: Article

References (36)

1. Benator, D., M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, R. Chaisson, F. Gordin, C. R. Horsburgh, J. Horton, A. Khan, C. Lahart, B. Metchock, C. Pachucki, L. Stanton, A. Vernon, M. E. Villarino, Y. C. Wang, M. Weiner, S. Weis, et al. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360:528-534.
2. Bonecini-Almeida, M. G., J. L. Ho, N. Boechat, R. C. Huard, S. Chitale, H. Doo, J. Geng, L. Rego, L. C. O. Lazzarini, A. L. Kritski, W. D. Johnson, Jr., T. A. McCaffrey, and J. R. L. Silva. 2004. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor β (TGF-β) and analysis of TGF-β receptors I and II in active tuberculosis. Infect. Immun. 72:2628-2634.
3. Brahmbhatt, S., G. F. Black, N. M. Carroll, N. Beyers, F. Salker, M. Kidd, P. T. Lukey, K. Duncan, P. van Helden, and G. Walzl. 2006. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin. Exp. Immunol. 146:243-252.
4. Burdz, T. V. N., J. Wolfe, and A. Kabani. 2003. Evaluation of sputum decontamination methods for Mycobacterium tuberculosis using viable colony counts and flow cytometry. Diagn. Microbiol. Infect. Dis. 47:503-509.
5. Carroll, N. M., M. Richardson, E. Engelke, M. de Kock, C. Lombard, and P. D. van Helden. 2002. Reduction of the rate of false-positive cultures of Mycobacterium tuberculosis in a laboratory with a high culture positivity rate. Clin. Chem. Lab. Med. 40:888-892.
6. Carroll, N. M., M. Richardson, P. D. van Helden, S. H. Gillespie, T. D. McHugh, A. S. de Boer, and D. van Soolingen. 2003. Criteria for identification of cross-contamination of cultures of Mycobacterium tuberculosis in routine microbiology laboratories. J. Clin. Microbiol. 41:2269-2270.
7. Chang, K. C., C. C. Leung, W. W. Yew, S. C. Ho, and C. M. Tam. 2004. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am. J. Respir. Crit. Care Med. 170:1124-1130.
8. Cicuttini, F. M., K. A. Byron, D. Maher, A. M. Wootton, K. D. Muirden, and J. A. Hamilton. 1995. Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis. Rheumatol. Int. 14:201-206.
9. Cottrez, F., and H. Groux. 2001. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J. Immunol. 167:773-778.
10. Demissie, A., M. Abebe, A. Aseffa, G. Rook, H. Fletcher, A. Zumla, K. Weldingh, I. Brock, P. Andersen, and T. M. Doherty. 2004. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4{delta}2. J. Immunol. 172:6938-6943.
11. de Visser, K. E., and W. M. Kast. 1999. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13:1188-1199.
12. Dheda, K., J. S. Chang, R. A. Breen, J. A. Haddock, M. C. Lipman, L. U. Kim, J. F. Huggett, M. A. Johnson, G. A. Rook, and A. Zumla. 2005. Expression of a novel cytokine, IL-4delta2, in HIV and HIV-tuberculosis co-infection. AIDS 19:1601-1606.
13. Ekerfelt, C., J. Ernerudh, and M. C. Jenmalm. 2002. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. J. Immunol. Methods 260:55-67.
14. Gondek, D. C., L. F. Lu, S. A. Quezada, S. Sakaguchi, and R. J. Noelle. 2005. cutting edge: contact-mediated suppression by CD4+ CD25+ regulatory cells involve a granzyme B-dependent, perforine-independent mechanism. J. Immunol. 174:1783-1786.
15. Hernandez-Pando, R., D. Aguilar, M. L. G. Hernandez, H. Orozco, and G. Rook. 2004. Pulmonary tuberculosis in BALB/c mice with nonfunctional IL-4 genes: changes in the inflammatory effects of TNF-α and in the regulation of fibrosis. Eur. J. Immunol. 34:174-183.
16. Johnson, B. J., I. Estrada, Z. Shen, S. Ress, P. Willcox, M. J. Colston, and G. Kaplan. 1998. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect. Immun. 66:2426-2433.
17. Kawashima, M., and P. Miossec. 2005. Effect of treatment of rheumatoid arthritis with infliximab on IFN{gamma}, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann. Rheum. Dis. 64:415-418.
18. Kritski, A. L., L. S. Rodrigues de Jesus, M. K. Andrade, E. Werneck-Barroso, M. A. Vieira, A. Haffner, and L. W. Riley. 1997. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 111:1162-1167.
19. McIlleron, H., M. L. Watkins, P. I. Folb, S. R. Ress, and R. J. Wilkinson. 2007. Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. Tuberculosis 87:557-564.
20. Miotto, D., P. Christodoulopoulos, R. Olivenstein, R. Taha, L. Cameron, A. Tsicopoulos, A.-B. Tonnel, O. Fahy, J. J. Lafitte, A. D. Luster, B. Wallaert, C. E. Mapp, and Q. Hamid. 2001. Expression of IFN-γ- inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. J. Allergy Clin. Immunol. 107:664-670.
21. Mistry, R., J. M. Cliff, C. L. Clayton, N. Beyers, Y. S. Mohamed, P. A. Wilson, H. M. Dockrell, D. M. Wallace, P. D. van Helden, K. Duncan, and P. T. Lukey. 2007. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J. Infect. Dis. 195:357-365.
22. Murphy, K. M., and S. L. Reiner. 2002. The lineage decisions of helper T-cells. Nat. Rev. Immunol. 2:933-943.
23. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor {beta}. J. Exp. Med. 194:629-644.
24. Roberts, T., N. Beyers, A. Aguirre, and G. Walzl. 2007. Immunosuppression during active tuberculosis is characterized by decreased interferon-gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor-beta, and interleukin-4 mRNA levels. J. Infect. Dis. 195: 870-878.
25. Rook, G. A., R. Hernandez-Pando, K. Dheda, and G. Teng Seah. 2004. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol. 25:483-488.
26. Sahiratmadja, E., B. Alisjahbana, S. Buccheri, D. Di Liberto, T. de Boer, I. Adnan, R. van Crevel, M. R. Klein, K. E. van Meijgaarden, R. H. H. Nelwan, E. van de Vosse, F. Dieli, and T. H. M. Ottenhoff. 2007. Plasma granulysin levels and cellular interferon-γ production correlate with curative host responses in tuberculosis, while plasma interferon-γ levels correlate with tuberculosis disease activity in adults. Tuberculosis 87:312-321.
27. Sugawara, I., H. Yamada, S. Mizuno, and Y. Iwakura. 2000. IL-4 is required for defense against mycobacterial infection. Microbiol. Immunol. 44:971-979.
28. Sullivan, B. M., O. Jobe, V. Lazarevic, K. Vasquez, R. Bronson, L. H. Glimcher, and I. Kramnik. 2005. Increased susceptibility of mice lacking T-bet to infection with Mycobacterium tuberculosis correlates with increased IL-10 and decreased IFN-{gamma} production. J. Immunol. 175:4593-4602.
29. Tam, C. M., S. L. Chan, K. M. Kam, R. L. Goodall, and D. A. Mitchison. 2002. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int. J. Tuberc. Lung Dis. 6:3-10.
30. van Crevel, R., T. H. M. Ottenhoff, and J. W. M. van der Meer. 2002. Innate immunity to Mycobacterium tuberculosis. Clin. Microbiol. Rev. 15:294-309.
31. Vasiliev, A. M., R. N. Vasilenko, N. L. Kulikova, S. M. Andreev, I. O. Chikileva, G. Y. Puchkova, I. V. Kosarev, A. V. Khodyakova, V. S. Khlebnikov, L. R. Ptitsyn, G. Y. Shcherbakov, V. N. Uversky, L. M. DuBuske, and V. M. Abramov. 2003. Structural and functional properties of IL-4delta2, an alternative splice variant of human IL-4. J. Proteome Res. 2:273-281.
32. Veenstra, H., R. Baumann, P. T. Lukey, N. Beyers, P. D. van Helden, and G. Walzl. 2008. High levels of intracellular IL-4 are expressed in circulating apoptotic T cells in patients with tuberculosis and in community controls. Tuberculosis 88:21-30.
33. World Health Organization. 2003. Treatment of tuberculosis guidelines for national programmes, 3rd ed. World Health Organization, Geneva, Switzerland.
34. Xu, W. G., Z. Gao, and B. D. Fan. 2003. Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy. Zhonghua Jie He He Hu Xi Za Zhi 26(1):74-76.
35. Zhu, J., H. Yamane, J. Cote-Sierra, L. Guo, and W. E. Paul. 2006. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 16:3-10.
36. Viola, J. P. B., and A. Rao. 1999. Molecular regulation of cytokine gene expression during the immune response. J. Clin. Immunol. 19:98-108.